Want to see ZNTL full AI Analyst Report?
Zentalis Pharmaceuticals (ZNTL) Financial Statements
Zentalis Pharmaceuticals Financial Overview
Zentalis Pharmaceuticals's market cap is currently $185.56M. The company's EPS TTM is $-2.46; its P/E ratio is -0.80; Zentalis Pharmaceuticals is scheduled to report earnings on November 11, 2026, and the estimated EPS forecast is $-0.54. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 67.42M | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ 67.42M | $ 0.00 | $ 0.00 | $ 0.00 |
| Operating Income | $ -152.81M | $ -191.19M | $ -299.51M | $ -227.29M | $ -216.54M |
| EBITDA | $ -144.27M | $ -186.17M | $ -247.60M | $ -233.58M | $ -207.20M |
| Net Income | $ -137.06M | $ -165.84M | $ -292.19M | $ -236.81M | $ -158.72M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 245.89M | $ 371.08M | $ 482.92M | $ 437.37M | $ 340.13M |
| Total Assets | $ 288.97M | $ 430.34M | $ 562.03M | $ 553.46M | $ 472.02M |
| Total Debt | $ 39.58M | $ 42.65M | $ 45.77M | $ 47.33M | $ 45.91M |
| Net Debt | $ 3.58M | $ 8.75M | $ 17.73M | $ 4.26M | $ -14.04M |
| Total Liabilities | $ 72.76M | $ 93.15M | $ 124.64M | $ 119.43M | $ 107.54M |
| Stockholders' Equity | $ 216.20M | $ 337.19M | $ 437.28M | $ 433.80M | $ 363.95M |
| Cash Flow | |||||
| Free Cash Flow | $ -125.25M | $ -171.08M | $ -208.41M | $ -166.30M | $ -160.20M |
| Operating Cash Flow | $ -125.25M | $ -170.86M | $ -207.82M | $ -163.75M | $ -154.09M |
| Investing Cash Flow | $ 131.62M | $ 176.56M | $ -44.46M | $ -114.18M | $ -18.11M |
| Financing Cash Flow | $ -4.28M | $ 108.00K | $ 237.30M | $ 261.04M | $ 178.52M |
Currency in USD